LIVERtera: Revolutionizing Cancer Research with In Silico Models and Liver Tumor Organoids

The development of effective treatments for liver cancer remains a challenge due to the complexity of tumor tissue and the difficulty in accurately replicating both its microenvironment and the behaviour of the human liver. LIVERtera (Integration of In Silico Models and Liver Tumor Organoids for the Identification and Validation of Therapeutic Targets) was created to tackle these challenges by combining the best of biotechnology and computational intelligence to accelerate the discovery of new cancer therapies.

By integrating patient-derived liver tumor organoids with cutting-edge in silico models, LIVERtera aims to optimize drug screening, making it faster, more precise, and more representative of clinical reality. This innovative approach enables:

• The creation of a biobank of liver tumor organoids for research and drug validation.

• The development of advanced in vitro and in silico models, improving the prediction of therapeutic efficacy.

• The establishment of an innovative preclinical service that integrates and optimizes drug screening through the combination of in silico and in vitro technologies.

This project is funded by the Center for Technological Development and Innovation (CDTI) and the Ministry of Science, Innovation and Universities. It is being carried out in collaboration with an international Spanish-Swiss consortium, composed by BeCytes Biotechnologies and Doppl SA. Both companies will work together on the development and optimization of in vitro and in silico models for studying liver tumors, covering organoid generation and cultivation, tissue characterization, and the development of advanced technologies.

Real Impact on Health and Society

By offering a more reliable and efficient system for selecting treatments, LIVERtera increases the success rate of clinical trials and fosters the development of more personalized and effective therapies. Additionally, the creation of an innovative preclinical service will enable faster and more meticulous drug screening, enhancing the clinical relevance of preclinical studies.

LIVERtera seeks to drive a disruptive change in precision oncology, promoting breakthroughs that will transform liver cancer treatment and benefit both patients and the scientific community.